
-
Bristol-Myers Squibb NYSE:BMY Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Location: Route 206 & Province Line Road, Princeton, NJ, 08543, United States | Website: https://www.bms.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
136.9B
Cash
11.78B
Avg Qtr Burn
N/A
Short % of Float
1.82%
Insider Ownership
0.08%
Institutional Own.
82.21%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Breyanzi® (lisocabtagene maraleucel) Details Follicular lymphoma, Cancer | Approved Quarterly sales | |
Breyanzi® (lisocabtagene maraleucel) Details Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma | Approved Quarterly sales | |
KRAZATI (Adagrasib) + Cetuximab Details Cancer, Colorectal cancer , Solid tumor/s | Approved Quarterly sales | |
Zeposia (ozanimod) Details Multiple sclerosis, Ulcerative colitis | Approved Quarterly sales | |
Breyanzi® (lisocabtagene maraleucel) Details Mantle cell lymphoma, Cancer | Approved Quarterly sales | |
Opdivo® (nivolumab) + chemotherapy Details Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
KRAZATI (Adagrasib) Details Cancer, Lung cancer, Non-small cell lung carcinoma, Solid tumor/s, Colorectal cancer | Approved Quarterly sales | |
Sotyktu (deucravacitinib) Details Psoriasis, Skin disease/disorder | Approved Quarterly sales | |
Augtyro™ (Repotrectinib) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Colorectal cancer , Cancer | Approved Quarterly sales | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Hepatocellular carcinoma | Approved Quarterly sales | |
Opdivo Qvantig™ Subcutaneous [(nivolumab + hyaluronidase (rHuPH20)] Details Cancer, Renal cell carcinoma | Approved Quarterly sales | |
Camzyos®(mavacamten) Details Hypertrophic cardiomyopathies | Approved Quarterly sales | |
COBENFY™ (xanomeline and trospium chloride) Details Mental health, Schizophrenia | Approved Quarterly sales | |
Abecma (idecabtagene vicleucel) Details Cancer, Melanoma | Approved Quarterly sales | |
Opdivo® (nivolumab) + Cisplatin-Based Chemotherapy Details Cancer, Urothelial carcinoma | Approved Quarterly sales | |
Eliquis Details Stroke, Atrial fibrillation, Blood clots | Approved Quarterly sales | |
Augtyro™ (Repotrectinib) Details Solid tumor/s, Cancer | Approved Quarterly sales | |
Reblozyl®(luspatercept-aamt) Details Cancer, Anemia, Blood cancer, Mutant Myelodysplastic Syndromes | Approved Quarterly sales | |
Opdivo® (nivolumab) Details Cancer, Melanoma | Approved Quarterly sales | |
OPDIVO (nivolumab) injection Details Gastric cancer, Gastroesophageal adenocarcinomas | PDUFA Approval decision | |
BMS-986278 [(LPA1) antagonist] Details Lung disease, Idiopathic pulmonary fibrosis | Phase 3 Data readout | |
Milvexian Details Acute coronary syndrome, Stroke, Atrial fibrillation | Phase 3 Data readout | |
KarXT (M1/M4 muscarinic agonist) Details Schizophrenia, Mental health, Alzheimer's disease | Phase 3 Data readout | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Non-small cell lung carcinoma, Cancer | Phase 3 Update | |
Zeposia (ozanimod) Details Crohns disease | Phase 3 Update | |
Opdivo® (nivolumab) + relatlimab w/ ENHANZE® Details Cancer, Melanoma | Phase 3 Update | |
Phase 3 Update | ||
KRAZATI (Adagrasib) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s | Phase 3 Update | |
Adagrasib (KRAZATI®) + Cetuximab Details Solid tumor/s, Colorectal cancer , Cancer | Phase 3 Update | |
Breyanzi® (lisocabtagene maraleucel) Details B-cell lymphoma | Phase 3 Update | |
Sotyktu (deucravacitinib) Details Psoriatic arthritis | Phase 3 Update | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Non-small cell lung carcinoma, Cancer | Phase 3 Update | |
Adagrasib (KRAZATI®) + Pembrolizumab Details Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 3 Update | |
A/I CELMoD (CC-99282) Details Relapsed/ refractory lymphoma, Non-Hodgkin lymphoma, Cancer | Phase 2 Interim update | |
Elzovantinib (TPX-0022) (MET inhibitor) Details Solid tumor/s, Cancer | Phase 2 Initiation | |
Adagrasib (KRAZATI®) + MRTX0902 Details Solid tumor/s | Phase 1/2 Data readout | |
MRTX1719 (PRMT5 inhibitor) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
Golcadomide (CELMoD™ Agent) +rituximab Details Blood cancer, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma | Phase 1/2 Update | |
MRTX1133 Details Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Lung cancer | Phase 1/2 Update | |
Adagrasib (KRAZATI®) + VS-6766 Details Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1/2 Initiation | |
Golcadomide (CELMoD™ Agent) Details Blood cancer, Non-Hodgkin lymphoma | Phase 1b Update | |
KarXT (M1/M4 muscarinic agonist) Details Schizophrenia | Phase 1b Update | |
KAR-2618 Details Mental health, Major depressive disorder | Phase 1b Initiation | |
BMS-986393/CC-95266 Details High Refractory Multiple Myeloma | Phase 1 Update | |
BMS-986365 (CC-94676) Details Castration-resistant prostate cancer | Phase 1 Update |